<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04381117</url>
  </required_header>
  <id_info>
    <org_study_id>EN3835-220</org_study_id>
    <nct_id>NCT04381117</nct_id>
  </id_info>
  <brief_title>Long-term Durability Study of CCH</brief_title>
  <official_title>A Phase 2b, Open-label Long-term Durability Study of CCH Following Treatment of Edematous Fibrosclerotic Panniculopathy (Cellulite)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the long-term safety and duration of efficacy of CCH in the
      treatment of women with cellulite. This study will be a single day evaluation, approximately
      48 months after the first dose of study drug was received in the EN3835-201.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 6, 2020</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CR-PCSS change from baseline (Day 1) and reference time point (Day 71) from the EN3835-201 study</measure>
    <time_frame>Approximately 4 weeks</time_frame>
    <description>Clinician Reported-Photonumeric Cellulite Severity Scale is a 5-level photonumeric scale with ratings ranging from 0 (None) to 4 (Severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PR-PCSS change from baseline (Day 1) and reference time point (Day 71) from the EN3835-201 study</measure>
    <time_frame>Approximately 4 weeks</time_frame>
    <description>Patient Reported-Photonumeric Cellulite Severity Scale is a 5-level photonumeric scale with ratings ranging from 0 (None) to 4 (Severe)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">7</enrollment>
  <condition>Edematous Fibrosclerotic Panniculopathy</condition>
  <arm_group>
    <arm_group_label>No Treatment</arm_group_label>
    <description>Subjects who participated in and completed study EN3835-201 and had composite improvement of at least 2-levels on both the CR-PCSS and PR-PCSS in EN3835-201 study will be eligible for this study. The study will consist of a single day evaluation approximately 4 years after the first dose of the study drug was received in the EN3835-201 study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Previously Treated with EN3835</intervention_name>
    <description>No treatment to be administered - Observational only</description>
    <arm_group_label>No Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The Durability Population, defined as all subjects in the Safety Population who have both
        CR-PCSS and PR-PCSS assessments at Visit 1 (Month 48).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have participated in and completed studies EN3835-201, EN3835-202 and EN3835-219 and
             had composite improvement of at least 2 levels on both the CR-PCSS and PR-PCSS in
             study EN3835-201.

          2. Be willing and able to cooperate with the requirements of the study.

        Exclusion Criteria:

          1. Has had retreatment with CCH in the area initially treated during the EN3835-201 study
             since the completion of study EN3835-219.

          2. Has received collagenase treatments (eg, Santyl速 Ointment and/or Xiaflex速/Xiapex速)
             since the completion of study EN3835-219.

          3. Has had liposuction on the body region treated during the EN3835-201 study since the
             completion of that study.

          4. Has had any surgery, invasive procedure (eg, liposuction), injectable treatment (eg,
             KYBELLA速) or any similar treatment in the area treated during the EN3835-201 study
             since the completion of that study.

          5. Has any other condition(s) that, in the investigator's opinion, might indicate the
             participant to be unsuitable for the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Chajko</last_name>
    <role>Study Director</role>
    <affiliation>Endo Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Site #4</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #2</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #3</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #1</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EFP</keyword>
  <keyword>Cellulite</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

